Abstract
AbstractIn the past decade, the development of immune checkpoint inhibitors in oncological clinical settings was in the forefront. However, the interest in musculoskeletal tumor patients as candidates for checkpoint inhibition remains underserved. Here, we are forwarding evidence proposing that galectin-3 (Gal-3) is an additional immune factor in the checkpoint processes. This review is the result of a large-scale cohort study depicting that overexpression of Gal-3 was widely prevalent in patients with musculoskeletal tumors, whereas T cell infiltrations were generally suppressed in the tumor microenvironment. Targeting Gal-3 would serve as a novel immune checkpoint inhibitor candidate in patients afflicted with aggressive musculoskeletal tumors.
Funder
Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan
Publisher
Springer Science and Business Media LLC
Reference50 articles.
1. Raz, A., Bucana, C., McLellan, W., & Fidler, I. J. (1980). Distribution of membrane anionic sites on B16 melanoma variants with differing lung colonising potential. Nature, 284(5754), 363–364. https://doi.org/10.1038/284363a0.
2. Raz, A., & Lotan, R. (1981). Lectin-like activities associated with human and murine neoplastic cells. Cancer Research, 41(9 Pt 1), 3642–3647.
3. Inohara, H., & Raz, A. (1994). Identification of human melanoma cellular and secreted ligands for galectin-3. Biochemical and Biophysical Research Communications, 201(3), 1366–1375. https://doi.org/10.1006/bbrc.1994.1854.
4. Nakajima, K., Kho, D. H., Yanagawa, T., Zimel, M., Heath, E., Hogan, V., & Raz, A. (2016). Galectin-3 in bone tumor microenvironment: a beacon for individual skeletal metastasis management. Cancer Metastasis Reviews, 35(2), 333–346. https://doi.org/10.1007/s10555-016-9622-4.
5. Nakajima, K., & Raz, A. (in submission). Galectin-3 expressional profile in musculoskeletal tumor patients.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献